| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
GCB-27a (1–1000 nM; 72 hours) effectively stimulated the production of Th1 cytokines by C57BL/6 mouse spleen cells in vitro, increased IFN-γ secretion at all tested concentrations, and no cytotoxicity was observed [1]. GCB-27a (100 nM; 2–24 hours) formed a more stable and longer-lasting complex with CD1d on the surface of mouse bone marrow-derived dendritic cells (BMDCs) than αGalCer, as measured by enhanced and prolonged binding to L363 antibody [1]. GCB-27a (24 hours) effectively induced the production of Th1 cytokines by human NKT cells, with twice the frequency of IFN-γ+ cells compared to αGalCer, and comparable levels of IL-4 induction [1]. Due to the optimization of hydrophobic interactions and conformational pre-organization within the CD1d A' pocket, GCB-27a exhibits stronger binding affinity for human and mouse CD1d than αGalCer[1].
|
|---|---|
| ln Vivo |
GCB-27a (2.33 nmol per mouse; intraperitoneal injection; single injection) can induce a strong Th1 immune response in BALB/c mice, with IFN-γ levels 10.9 times higher than αGalCer, while maintaining IL-4 levels comparable to αGalCer [1]. GCB-27a (2.33 nmol per mouse; intraperitoneal injection; single injection) can effectively activate innate immune cells in C57BL/6 mice, enhance the expression of dendritic cell (DC) maturation markers, and increase the frequency of natural killer (NK) cells secreting IFN-γ [1]. GCB-27a (0.58 nmol per mouse; intraperitoneal injection; single injection) showed strong anti-tumor efficacy in a mouse melanoma lung metastasis model, reducing the number of metastatic nodules by 89% compared to αGalCer through a sustained Th1 immune response [1].
|
| Animal Protocol |
Animal/Disease Models:BALB/c mice (n=5)[1]
Doses: 2.33 nmol per mouse Route of Administration: Intraperitoneal injection; single injection Experimental Results: 24 hours after injection, serum IFN-γ levels increased 10.9-fold compared to αGalCer. IL-4 levels remained at levels comparable to αGalCer. Among all tested analogs, this analog exhibited the strongest Th1 selectivity, with the highest fold change in the IFN-γ/IL-4 ratio compared to αGalCer. Its sustained Th1 bias activity was confirmed by time-dependent cytokine analysis, and a peak IFN-γ level was observed 24 hours after injection. Animal/Disease Models:C57BL/6 mice (n=3)[1] Doses: 2.33 nmol per mouse Route of Administration: Intraperitoneal injection; single injection Experimental Results: Compared with αGalCer, the expression of CD80 and CD86 on CD11c+ dendritic cells (DCs) was significantly increased. The frequency of IFN-γ-producing NK cells in the spleen increased to about 20%, which was significantly increased compared with αGalCer. Animal/Disease Models:C57BL/6 mice (n=6; melanoma lung metastasis model) [1] Doses: 0.58 nmol per mouse Route of Administration: Intraperitoneal injection; single injection Experimental Results: Serum IFN-γ levels were significantly increased compared to the αGalCer group, while IL-4 levels were comparable to those in the αGalCer group. The number of lung metastatic nodules was reduced by 89% compared to the αGalCer group. Histological analysis showed that lung metastasis was almost completely suppressed. |
| References |
| Molecular Formula |
C52H95NO10
|
|---|---|
| Molecular Weight |
894.31
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
O[C@H]1[C@@H](CO)O[C@H](OC[C@H](NC(CC2=CC=C(OCC(CCCCCCCC)CCCCCCCCCC)C=C2)=O)[C@H](O)[C@H](O)CCCCCCCCCCCCCC)[C@H](O)[C@H]1O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1182 mL | 5.5909 mL | 11.1818 mL | |
| 5 mM | 0.2236 mL | 1.1182 mL | 2.2364 mL | |
| 10 mM | 0.1118 mL | 0.5591 mL | 1.1182 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
